Methods for the selection of platelet products for alloimmune-refractory patients

Transfusion

Volumn 55, Issue 2, 2015, Pages 235-244

  Kopko, Patricia M ^a   Warner, Paul ^b   Kresie, Lesley ^c   Pancoska, Carol ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

^c Carter BloodCare   (United States)

^d EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; EPITOPE; HLA ANTIBODY; HLA ANTIGEN; PANEL REACTIVE ANTIBODY;

ALLOIMMUNITY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; ERYTHROCYTE ADHESIVENESS; FLOW CYTOMETRY; HISTOCOMPATIBILITY TEST; HLA MATCHING; HLA TYPING; HUMAN; IMMUNOASSAY; LUMINEX SINGLE BEAD ASSAY; PLATELET TRANSFUSION REFRACTORINESS; SOLID PHASE RED CELL ADHERENCE; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; TRANSFUSION MEDICINE; TREATMENT FAILURE; TREATMENT RESPONSE; BLOOD; CYTOLOGY; IMMUNOLOGY; METABOLISM; PROCEDURES; THROMBOCYTE;

BLOOD PLATELETS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; ISOANTIBODIES; PLATELET TRANSFUSION;

EID: 84923038492     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12921     Document Type: Article

References (26)

1. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion interval in thrombocytopenic patients. Blood 2005; 105: 4106-4114.
2. Saito S, Ota S, Seshimo H, et al. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 2002; 42: 302-308.
3. McFarland JG,. Platelet and granulocyte antigens and antibodies. In:, Roback JD, editor. AABB technical manual. 17th ed. Bethesda (MD): AABB Press; 2011. p. 523-545.
4. Hod E, Schwartz J,. Platelet transfusion refractoriness. Br J Haematol 2008; 142: 348-360.
5. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861-1869.
6. Terasaki PI, McClelland JD,. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998-1000.
7. Cecka JM,. Calculated PRA (cPRA): the new measure of sensitization for transplant candidates. Am J Transplant 2010; 10: 26-29.
8. Smith JD, Hamour IM, Banner NR, etal. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809-2815.
9. Jackman RP, Deng X, Bolgiano D, et al. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood 2013; 121: 3261-3266.
10. Zachary AA, Vega RM, Lucas DP, et al. HLA antibody detection and characterization by solid phase immunoassays: methods and pitfalls. Methods Mol Biol 2013; 882: 289-308.
11. Tait BD, Hudson F, Brewin G, et al. Solid phase HLA antibody detection technology-challenges in interpretation. Tissue Antigens 2010; 76: 87-95.
12. Schwaiger E, Wahrmann M, Bond G, et al. Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation 2014; 97: 1279-1285.
13. Eng HS, Leffell MS,. Histocompatibility testing after fifty years of transplantation. J Immunol Methods 2011; 369: 1-21.
14. Erlich H,. HLA DNA typing: past, present, and future. Tissue Antigens 2012; 80: 1-11.
15. Rachel JM, Summers TC, Sinor LT, et al. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988; 90: 63-68.
16. Wiita AP, Nambiar A,. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes. Transfusion 2012; 52: 2146-2154.
17. Vassallo RR, Fung M, Rebulla P, et al. Utility of cross-matched platelet transfusion in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2014; 54: 1180-1191.
18. Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-1456.
19. Fontaine MJ, Kuo J, Chen G, et al. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. Transfusion 2011; 51: 2611-2618.
20. Duquesnoy RJ, Askar M,. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 2007; 68: 12-25.
21. Duquesnoy RJ,. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 2011; 77: 525-534.
22. Pai S, Lo S, Tsai SL, et al. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 2010; 50: 2318-2327.
23. Julmy F, Ammann RA, Taleghani BM, etal. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical platelets. Transfusion 2009; 40: 21-33.
24. Curtis BR, Edwards JT, Hessner MJ, et al. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000; 96: 1574-1581.
25. McVey M, Cserti-Gazdewich CM,. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA. Transfus Med 2010; 20: 346-353.
26. Schiffer CA, O'Connell B, Lee EJ,. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets. Blood 1989; 74: 1172-1176.